The First 90 Days: US Biopharmaceutical Finished Goods Supply Chain Response to COVID-19
Developed in collaboration with Deloitte Consulting LLP, this report examines the role that the supply chain played in delivering medicines safely and efficiently to patients during the unprecedented early days of the COVID-19 pandemic.
The First 90 Days: US Biopharmaceutical Finished Goods Supply Chain Response to COVID-19 analyzes the challenges faced by the industry in the initial stages of the pandemic, and evaluates its performance in:
- Handling demand surges for critical medicines;
- Minimizing supply disruptions;
- Maintaining operations while preserving workplace safety; and,
- Supporting the nation’s evolving public health agenda.
Implications of scenarios that could unfold within the next 6 to 12 months as well as recommendations for the industry to build resilience to future disruptions are provided.
Publication SponsorsGold: Cardinal Health, Inc.; CuraScript SD; Novartis Pharmaceuticals Corporation; PAR Pharmaceutical an Endo International Company
Bronze: Ascend Laboratories, LLC; IQVIA; Upsher-Smith Laboratories, LLC